广东博卓医药科技

Bozhuo Pharmaceutical is a clinical-stage biotechnology company based in Guangzhou, China, specializing in the discovery and development of novel small molecule therapeutics. The company's primary focus is on the ubiquitin-proteasome system, particularly targeting deubiquitinating enzymes to treat cancer and immune-related disorders. Its lead candidate, BZ-001, is a highly selective USP7 inhibitor currently undergoing Phase 1 clinical trials for advanced solid tumors. Bozhuo Pharmaceutical leverages its internal R&D platform to advance a pipeline of precision medicines designed to overcome drug resistance. The company is strategically located in the Guangzhou International Bio-island, a major hub for biotech innovation in Southern China. By focusing on first-in-class targets, Bozhuo aims to provide innovative solutions for patients with unmet medical needs in oncology.